The China Food and Drug Administration on Thursday announced a three-year pilot program, effective immediately, that will allow research and development outfits in ten regions to seek approvals for new drugs, a privilege currently enjoyed only by drug manufacturers, Reuters reported, citing a statement on the administration’s website. Current rules make it difficult for research-based firms to bring new drugs to market because they need to invest in expensive manufacturing plants before seeking approval. The trial will take place in municipalities including Beijing and Shanghai as well as provinces including Guangdong and Zhejiang.
You must log in to post a comment.
Yes, I would like to receive emails from China Economic Review. (You can unsubscribe anytime)
Copyright © 2018 SinoMedia Group Limited All rights reserved